Presidential Trainees

Chat with the 2022 Presidential Trainees during the Presidential Trainee Showcase on Wednesday, March 16th from 6:15 PM - 7:15 PM ET.

Presidential Trainees

Type here to filter the list

PT-001 - COMPARATIVE ANALYSIS OF THE RB PATHWAY IN LEIOMYOSARCOMA.

Favorite
PT-002 - DEVELOPMENTAL PHARMACOKINETICS AND PHARMACOGENOMICS OF ISONIAZID IN PREDOMINANTLY LOW-BIRTH-WEIGHT OR PRETERM INFANTS WITH OR WITHOUT HIV EXPOSURE.

Favorite
PT-003 - CORONARY HEART DISEASE POLYGENIC RISK SCORE MODIFIES STATIN RELATIVE RISK REDUCTION FOR THE PRIMARY PREVENTION OF MYOCARDIAL INFARCTION IN A REAL-WORLD COHORT.

Favorite
PT-004 - PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF PRIMARY CLINICAL OUTCOMES IN TREATING DRUG-SENSITIVE TUBERCULOSIS WITH FOUR-MONTH HIGH-DOSE RIFAPENTINE WITH AND WITHOUT MOXIFLOXACIN (STUDY 31/A5349).

Favorite
PT-005 - IDENTIFICATION OF A DISTAL ENHANCER AND REGULATORY VARIANTS CONTROLLING EXPRESSION OF THE CYP3A GENES.

Favorite
PT-006 - HYPOALBUMINEMIA EARLY IN TREATMENT HINDERS BENEFIT FROM IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH ADVANCED CANCERS.

Favorite
PT-007 - OPTIMIZING DIHYDROARTEMISININ-PIPERAQUINE REGIMENS FOR MALARIA PREVENTION IN PREGNANT WOMEN USING REPEATED ECG AND PARASITE DENSITY MEASURES.

Favorite
PT-008 - PHARMACOGENOMIC GENOME-WIDE META-ANALYSIS TO IDENTIFY VARIANTS ASSOCIATED WITH THIAZIDE AND THIAZIDE-LIKE DIURETIC INDUCED GLUCOSE CHANGE.

Favorite
PT-009 - PREVENTION OF OXALIPLATIN NEUROPATHY BY DULOXETINE-MEDIATED OCT2 INHIBITION.

Favorite
PT-010 - WEIGHT-BASED DOSING IS NOT NEEDED FOR RIFAMPICIN FOR PATIENTS WITH TUBERCULOSIS (TB): PK EVIDENCE FROM TBTC STUDY S31/A5349 (STUDY S31).

Favorite
PT-011 - INVESTIGATION OF CARDIOVASCULAR OUTCOMES IN BLACK PATIENTS FOLLOWING IMPLEMENTATION OF CYP2C19 GENOTYPE-GUIDED ANTIPLATELET THERAPY IN A REAL-WORLD CLINICAL SETTING.

Favorite
PT-012 - PHARMACOGENOMIC SINGLE NUCLEOTIDE POLYMORPHISM (SNP) SCORES AS A TOOL TO PREDICT TOXICITY PHENOTYPES IN TREATMENT OF ACUTE CHILDHOOD LEUKEMIA (ALL).

Favorite
PT-013 - CORTISOL REGULATES ALTERNATIVE POLYADENYLATION IN A GENOTYPE-DEPENDENT MANNER: GLUCOCORTICOID-DEPENDENT PHARMACOGENOMIC ALTERNATIVE POLYADENYLATION QUANTITATIVE TRAIT LOCI (PGx-3’aQTLs).

Favorite
PT-014 - RISK STRATIFICATION WITH PRE-TREATMENT METABOLITE RISK SCORE FOR CARFILZOMIB-RELATED CARDIOTOXICITY IN MULTIPLE MYELOMA PATIENTS.

Favorite
PT-015 - CHARACTERIZATION OF CAR-T CELLULAR KINETICS AND EFFICACY IN PATIENTS WITH SOLID TUMORS IN PRESENCE OR ABSENCE OF PRIOR LYMPHODEPLETION CHEMOTHERAPY USING A PBPK-PD MODEL.

Favorite
PT-016 - POLYGENIC RISK SCORES FOR BLOOD PRESSURE MAY PREDICT RISK OF SEVERE BEVACIZUMAB-INDUCED HYPERTENSION IN CANCER PATIENTS.

Favorite
PT-017 - CLINICAL PHARMACOLOGY POSTMARKETING STUDIES: A US FDA EVALUATION OF KNOWLEDGE GAPS AND TRANSLATION INTO LABELING.

Favorite
PT-018 - A POLYGENIC DNA DAMAGE REPAIR PHARMACOGENOMICS (DDR_PGX) SCORE PREDICTS RESPONSE TO GEMTUZUMAB OZOGAMICIN IN PEDIATRIC AML PATIENTS.

Favorite
PT-019 - UNCOVERING THE DISPROPORTIONAL IMPACT OF CHRONIC KIDNEY DISEASE ON THE RENAL SECRETION OF DRUGS VIA ORGANIC ANION TRANSPORTERS (OAT) 1 AND 3.

Favorite
PT-020 - IMPACT OF CYP2C19 GENOTYPE ON PREDICTION OF CARDIOVASCULAR EVENTS WITH THE ABCD-GENE SCORE AMONG PATIENTS RECEIVING CYP2C19-GUIDED ANTIPLATELET THERAPY AFTER PCI.

Favorite
PT-021 - DEVELOPMENT OF A TRANSLATIONAL PBPK-PD FRAMEWORK TO CHARACTERIZE CELLULAR KINETICS AND BIODISTRIBUTION OF CAR-T CELLS IN MICE AND CANCER PATIENTS.

Favorite